Seneca Foods Corporation reported a 7.1% increase in net sales to $492.59 million for its fiscal second quarter ended September 26, 2026, driven by higher prices, product mix, and sales volume. Despite the sales growth, net earnings slightly declined to $29.23 million from $29.74 million the previous year, and diluted earnings per share fell marginally to $4.27. The gross margin decreased to 12.5% from 13.4%, influenced by a $7.2 million LIFO charge this quarter compared to a $7.7 million LIFO credit last year. Excluding these inventory accounting effects, the gross margin actually improved year over year. Seneca Foods, which produces canned, frozen, and jarred fruits and vegetables, operates 27 facilities across nine states and recently filed its unaudited Form 10-Q on November 4.
Seneca Foods Corporation's quarterly sales and earnings were reported as of November 6, 2026, 07:02 WIB. For readers following major cryptocurrencies on Pluang, here is the market snapshot: out of 50 priced cryptocurrencies, 3 rose and 46 fell today. Notable movers include SNX at Rp2.944 with a 10.08% decline, FIL at Rp14.305 with a 9.92% decline, and CRV at Rp4.565 with a 9.24% decline.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Stacks (STX) surged 9.99% to $0.360, leading gains among the 90 largest cryptocurrencies as 77 advanced over 24 hours. Other notable winners included Injective (INJ) up 9.37%, Pearl (PEARL) up 8.29%, Render (RENDER) up 7.26%, and PancakeSwap (CAKE) u...
Perspective Therapeutics presented new Phase 1/2a trial data showing that bamzireotide (VMT-α-NET) achieved durable disease control and promising tumor responses in patients with advanced neuroendocrine tumors expressing SSTR2. Among 57 patients with...
